On February 23, 2021 The Lung Cancer Research Foundation (LCRF) reported a collaboration with AstraZeneca to fund over $900,000 in research grants focused on understanding resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) and immune checkpoint inhibitors (ICIs), including therapeutic approaches to overcome these mechanisms, as well as biomarkers of immune-mediated adverse events (Press release, AstraZeneca, FEB 23, 2021, View Source [SID1234575494]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Lung cancer is currently the number one cause of cancer death both in the U.S. and globally among both men and women. An estimated 625 new cases are diagnosed in the U.S. every day. As research funding grows, new treatments become available and survival rates improve. Promising new treatment options exist including targeted therapies and immunotherapies. Certain patients with non-small cell lung cancer (NSCLC) may benefit from targeted therapies which interfere with specific molecules involved in the growth and progression of cancer. For example, patients with EGFR mutation positive NSCLC can frequently benefit from treatment with EGFR tyrosine kinase inhibitors (TKIs). Despite clinical improvement with these therapies, acquired resistance invariably develops and insights into the mechanisms of resistance are needed as well as approaches to overcome and/or prevent resistance.
Over $900,000 in Research Grants Focused on Resistance to EGFR Tyrosine Kinase Inhibitors (TKIs) and Immunotherapies
ICIs, which function by enhancing the body’s immune response against cancer, have also led to profound improvements in the treatment of both locally advanced and metastatic NSCLC. Sustained clinical benefit of ICIs is not uniformly observed, however, and biological insights and biomarkers are needed to better guide patient selection to maximize their therapeutic benefit.
This collaboration seeks to support research studies that focus on understanding mechanisms of primary and acquired resistance to 3rd generation EGFR TKIs, and to identify more effective approaches to predict response and recurrence in patients treated with ICIs in locally advanced NSCLC. This collaboration will also promote advancing scientific knowledge in early stage and resectable NSCLC, including identification of predictive biomarkers of disease recurrence.
"LCRF is honored to continue its fifteen-year legacy of identifying and supporting outstanding lung cancer research projects over the years. We are excited to partner with AstraZeneca, who continues to be a generous supporter of our mission," said Katerina Politi, PhD, Chair, LCRF Scientific Advisory Board. "The specific focus of this grant program is to study treatment resistance and how that resistance may be overcome or prevented, addressing this very important issue that affects many lung cancer patients undergoing treatment."